MOUNTAIN VIEW, Calif., Nov. 8, 2010 (GLOBE NEWSWIRE) -- Conceptus, Inc. (Nasdaq:CPTS),developer of the Essure® procedure, the most effective non-surgical permanent birth control method available, today announced that the clinical and commercial success of the Essure procedure will be highlighted at the 39TH AAGL Global Congress of Minimally Invasive Gynecology in Las Vegas, Nevada, November 8-12, 2010.
The Essure procedure, which was FDA approved in 2002 and has been marketed internationally since 2001, will have more than 20 presentations featured at AAGL including abstracts, posters, videos and scientific virtual posters from presenters around the world who consider Essure the leading procedure for hysteroscopic sterilization. Among the presentations are:
- Hysteroscopic Placement of Essure Device in an Office Setting: A Critical Analysis; Chudnoff S, To J, Palmer S, Levie M
- Essure Transcervical Tubal Sterilization: A 5 Year X-Ray Follow Up; Franchini M, Boeri C, Imperatore A, Calzolari S, Litta P, Florio P
- Success of Essure Micro-Inserts in the Treatment of Hydrosalpinges Prior to In Vitro Fertilization (IVF) and Frozen Embryo Transfer (FET) Cycles and Pregnancy Outcomes; Nichols JE, West JR
In addition, AAGL's prestigious Golden Hysteroscope Award, which recognizes the year's best hysteroscopic paper, will be presented to Dr. John Thiel of the University of Saskatchewan for his study entitled, "A Randomized Double Blind Placebo Controlled Clinical Trial of Intravenous Conscious Sedation and Oral Analgesia for the Essure Permanent Birth Control Procedure."
Conceptus will be an active participant in several conference activities, which primarily focus on the continuing education of residents and fellows. For example, the Company will host educational labs for AAGL's post graduate courses, as well as sponsor a tradeshow booth. Additionally, Conceptus will host AAGL's first-ever VIP Residents and Fellows Lounge, which will provide an opportunity to train on the Company's state-of-the-art EssureSim(TM) simulator that replicates the Essure procedure.
About the Essure® Procedure
The Essure procedure, FDA approved since 2002, is the first permanent birth control method that can be performed in the comfort of a physician's office in less than 10 minutes (average hysteroscopic time) without hormones, cutting, burning or the risks associated with general anesthesia or tubal ligation. Soft, flexible inserts are placed in a woman's fallopian tubes through the cervix without incisions. Over the next three months, the body forms a natural barrier around the micro-inserts to prevent sperm from reaching the egg. Essure is 99.95% effective based on one year of follow up with zero pregnancies reported in clinical trials, making it the most effective form of permanent birth control on the market. The procedure is covered by most insurance plans, and when it is performed in a doctor's office the cost to the patient may be as low as a simple co-pay.
Three months after the Essure procedure, a doctor is able to perform an Essure Confirmation Test to confirm that the inserts are properly placed and the fallopian tubes are fully blocked, giving the patient reliance on Essure for permanent birth control. The Essure procedure has been proven and trusted by physicians since 2002, with more than 465,000 women worldwide having undergone the Essure procedure.
About Conceptus, Inc.
Conceptus, Inc. is a leader in the design, development and marketing of innovative solutions in women's healthcare. The Company manufactures and markets the Essure permanent birth control procedure. The Essure procedure is available in the United States, Europe, Australia, New Zealand, Canada, Mexico, Central and South America and the Middle East.
Please visit www.essure.com for more information on the Essure procedure. Patients may call the Essure Information Center at 1-877-ESSURE-1 with questions or to find a physician in their area.
The Conceptus, Inc. logo is available at
© 2010 Conceptus, Inc-- All rights reserved. Conceptus, Essure and Your Family is Complete. Your Choice is Clear are registered trademarks and service marks of Conceptus, Inc.
CC-2574 8NOV10F
CONTACT: Conceptus, Inc. Investor Relations and Public Relations Contact: Cindy Klimstra (650) 962-4032 cindy_klimstra@conceptus.com